GlaxoSmithKline plc’s Dividends Set To Reach 5.4%!

The City is forecasting a return to earnings growth for GlaxoSmithKline plc (LON: GSK), too.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The latest big news for GlaxoSmithKline (LSE: GSK) (NYSE: GSK) is its new deal with Novartis — some assets will be transferred in one direction, others in the opposite direction, and there will be a new joint venture to deal with a lot of the two companies’ consumer products.

It seems like a good idea for each company to focus on what it does best, though it will take some time for that to feed through to the bottom line.

Strong outlook

But for GlaxoSmithKline at least, any benefits will add to what is already looking like a decent outlook for the company over the next couple of years.

GlaxoSmithKlineThrough its vast product diversification and a big financial commitment to its drugs-development pipeline, Glaxo has been coping with the effects of the patent cliff pretty well — some blockbusters have lost patent protection and there is increasing competition from generic alternatives.

And while some may have expected a few years of falling earnings, as currently experienced by rival AstraZeneca, Glaxo has managed to keep its earnings stable — analysts are expecting just a 2% fall in earnings per share (EPS) for the year to December 2014. And while the AstraZenenca dividend was frozen, Glaxo’s has kept on growing.

Return to growth

For 2015, there’s a return to growth with a 9% EPS rise on the cards — and that all-important dividend is set to rise again, from an expected yield of 5.2% this year to 5.4% on today’s 1,650p price level.

gskThe trend in the analysts’ consensus, however, has been downwards — as it has been with a lot of the FTSE’s top shares over the past 12 months. A year ago, we were looking at a consensus for 2014 earnings of 125p per share, though that has steadily falling and the City boys are now expecting 110p. It’s a disappointing drop, but it does still leave the shares on a forward P/E of 15, and that’s lower than the current average.

Forecasts for 2015 have fallen in line, with a mooted EPS figure of 131p three months ago being downgraded to 119p today — but that drops the P/E to 14, which is attractive.

The trend in dividend forecasts has been more encouraging, with the 2014 forecast having been dropped by only a penny from the 81.8p the analysts were predicting a year ago to 80.8p today. It won’t be very well covered by earnings, but it should be safe enough.

Cautious for now

With such a cautious trend, it’s perhaps not surprising to see the bulk of around 30 analysts sticking to a Hold recommendation at the moment — but that could change when they’ve had time to scratch their heads over the Novartis tie-up.

The next few months should be interesting for Glaxo watchers.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan does not own any shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »